Skip to main content

Global Monoclonal Antibody Therapeutics Market growth fueled by innovation at 12% CAGR by 2030.

 The global monoclonal antibody therapeutics market is set to witness a growth rate of ~12% in the next 5 years. Rising prevalence of chronic and autoimmune diseases, advancements in the technologies related to drug engineering and development, increased funding and investments into research and development, approval of monoclonal antibody therapies, increased acceptance of personalized medicine, and expanding applications of mAB therapy in various medical fields, are some of the key factors driving the monoclonal antibody therapeutics market. 

Monoclonal antibodies (mAbs) are antibodies produced by a clonal population of B cells and bind to a single target antigen. A therapeutic mAb is a homogenous collection of antibodies used to treat illnesses. mAbs are selected based on their affinity for a target antigen. The target can be a plasma protein, infectious organism, cell surface antigen, or IgG receptor, depending on the mechanism of treatment. mAbs are used in immunotherapies in different ways, like to stimulate the patient’s immune system, to modulate/inhibit a biochemical disease pathway to deliver a therapeutic radionuclide or drug to a target cell type. Therapeutic mAbs exhibit much higher specificity than small molecule drugs, which minimizes adverse side effects, especially when highly toxic drug substances must be delivered.

🔗 Want deeper insights? Download the sample report here:
 https://meditechinsights.com/monoclonal-antibody-therapeutics-market/request-sample/

Increasing prevalence of chronic and autoimmune diseases to drive market growth

Severity and prevalence of chronic and autoimmune diseases are the key factors driving the market for mAB therapeutics. In 2023, 76.4% of adults over the age of 18 in the US were suffering from at least one chronic illness, this marks an increase from 72.3% reported in 2013. In addition, participants with multiple chronic conditions (two or more) also showed an increase from 47.3% to 51.4% during the same time period (Source: CDC). Furthermore, autoimmune diseases affect 5 to 10% of the population in industrialized countries (Source: Global Autoimmune Institute). The growing prevalence of such chronic and autoimmune diseases is driving the global need for mAbs or monoclonal antibodies which are precise and strongly effective directed therapies. The high specificity of mAbs helps in protecting healthy tissues from damage which greatly improves outcomes. mAbs are most suitable for the treatment of complex immune related disorders due to their ability to target disease related epitope markers, leading to increased mAbs market growth.

Advancements in the technologies related to drug engineering and development to propel market growth

Advancements in the drug engineering and therapy development technologies are propelling the growth of the monoclonal antibody therapeutics market. Modern advances, including recombinant DNA, high-throughput screening, and complex cell line development, have pushed therapies to the limits of efficacy, safety, and specificity of treatment with monoclonal antibodies. These approaches enable production of both humanized and completely human, as shielded, or bispecific antibodies as well as those with improved therapeutic indexes and less side effects. In addition, the efficacy of mAb of cancer and other diseases can be increased by antibody-drug conjugates (ADCs) combining mAbs specificity and potently active drugs. These improvements shorten the timescale taken to develop drugs and reduce production expenses, expanding the scope of treatable conditions and rendering the market bigger.

Competitive Landscape Analysis

The global monoclonal antibody therapeutics market is marked by the presence of established and emerging market players such as F. Hoffmann-La Roche Ltd; AbbVie Inc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb (BMS); Amgen Inc.; Novartis AG; Eli Lilly and Company; Sanofi; and AstraZeneca; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Get PDF Report for Competitive Analysis:
https://meditechinsights.com/monoclonal-antibody-therapeutics-market/request-sample/

 Global Monoclonal Antibody Therapeutics Market Segmentation

This report by Medi-Tech Insights provides the size of the global monoclonal antibody therapeutics market at the regional- and country-level from 2023 to 2030. The report further segments the market based on source, application, end user.

Market Size & Forecast (2023-2030), By Source, USD Million

  • Human Source

  • Humanized Source

  • Chimeric Source

  • Others

Market Size & Forecast (2023-2030), By Application, USD Million

  • Oncology

  • Autoimmune Diseases

  • Infectious Diseases

  • Hematologic Diseases

  • Ophthalmology

  • Others

Market Size & Forecast (2023-2030), By End User, USD Million

  • Hospitals

  • Long-term Care Facilities

  • Others

Market Size & Forecast (2023-2030), By Region, USD Million

  • North America

    • US

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia Pacific

    • China

    • India

    • Japan

    • Rest of Asia Pacific

  • Latin America

  • Middle East & Africa

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
  +32 498 86 80 79
  info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Digital Pharmaceutical Supply Chain Management Market Sees Increasing Demand with 9% CAGR Until 2030

  The   digital pharmaceutical supply chain management market is projected to grow at a CAGR of 9% from 2025 to 2030.  The growth is driven by the increasing need for enhanced supply chain transparency, demand for temperature-sensitive drug handling, and the shift towards digitization in healthcare operations. However, the high implementation cost and data privacy concerns are notable restraints. The digital pharmaceutical supply chain management includes integration of advanced technologies like AI, blockchain, IoT, and data analytics into the pharmaceutical supply chain. This integration enhances transparency, efficiency, and traceability across sourcing, manufacturing, and distribution processes. The market is vital for ensuring drug safety, mitigating counterfeiting risks, and optimizing logistics. These solutions also aid in regulatory compliance by offering real-time insights and data for reporting. 🔗 Want deeper insights? Download the sample report here: h...
Post a Comment
Read more

Contrast Media APIs Market Evolving Healthcare Needs and Future Business Prospects CAGR 5% by 2030

  The global contrast media APIs market is set to witness a growth rate of 5% in the next 5 years.  Rising volume of diagnostic imaging procedures; technological advancements in imaging modalities; expansion of healthcare infrastructure in emerging markets; rising R&D investments to develop safer and more effective contrast agents, are some of the key factors driving the contrast media APIs market. Contrast media APIs are the primary compounds used in the formulation of contrast agents, which enhance the visibility of internal structures in diagnostic imaging. These APIs play a crucial role in modalities like  computed tomography  (CT),  magnetic resonance imaging  (MRI), and ultrasound by improving the differentiation between tissues, organs, and blood vessels. Typically derived from iodine or gadolinium, they are formulated to ensure solubility, stability, and patient safety during procedures. The manufacturing of contrast media APIs involves stric...
Post a Comment
Read more

Global Healthcare Payer Services Market: AI, Big Data & 8% CAGR Growth Forecast by 2030

  The healthcare payer services market is expected to grow at a CAGR of approximately 8% from 2025 to 2030.  Key drivers include the rising demand for cost-effective healthcare solutions, increased adoption of digital platforms, regulatory changes mandating operational transparency, the surge in healthcare data, and the growing need for fraud prevention mechanisms. However, challenges such as data security concerns and integration complexities act as significant restraints. The healthcare payer services market encompasses a range of administrative, operational, and financial services provided to healthcare payers, including insurance companies, government agencies, and employer groups. These services aim to enhance efficiency, reduce costs, and improve customer satisfaction. Offerings include claims processing, member management, provider management, and analytics for decision-making. The market leverages advanced technologies such as artificial intelligence and cloud compu...
Post a Comment
Read more